Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement

Katherine E. Miller1,2*, Gregory Wheeler1, Stephanie LaHaye1, Kathleen M. Schieffer1,2,3, Sydney Cearlock1, Lakshmi Prakruthi Rao Venkata1, Alejandro Otero Bravo1, Olivia E. Grischow1, Benjamín J. Kelly1, Peter White1,2, Christopher R. Pierson3,4,5, Daniel R. Boué3,4,5, Selene C. Koo6, Darren Klawinski7,8, Mark A. Ranalli2,7, Ammar Shaikhouni9,10, Ralph Salloum2,7,8, Margaret Shatara11, Jeffrey R. Leonard2,6,9,10, Richard K. Wilson1,2, Catherine E. Cottrell1,2,3, Elaine R. Mardis1,2,10, and Daniel C. Koboldt1,2*

1 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States, 2 Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States, 3 Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, United States, 4 Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH, United States, 5 Department of Biomedical Education and Anatomy, Division of Anatomy, The Ohio State University College of Medicine, Columbus, OH, United States, 6 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, United States, 7 Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, OH, United States, 8 Pediatric Neuro-Oncology Program, Nationwide Children’s Hospital, Columbus, OH, United States, 9 Department of Hematology and Oncology, St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO, United States

Rhabdoid tumors (RTs) of the brain (atypical teratoid/rhabdoid tumor; AT/RT) and extracranial sites (most often the kidney; RTK) are malignant tumors predominantly occurring in children, frequently those with SMARCB1 germline alterations. Here we present data from seven RTs from three pediatric patients who all had multi-organ involvement. The tumors were analyzed using a multimodal molecular approach, which included exome sequencing of tumor and germline comparator and RNA sequencing and DNA array-based methylation profiling of tumors. SMARCB1 germline alterations were identified in all patients and in all tumors. We observed a second hit in SMARCB1 via chr22 loss of heterozygosity. By methylation profiling, all tumors were classified as rhabdoid tumors with a corresponding subclassification within the MYC, TYR, or SHH AT/RT subgroups. Using RNA-seq gene expression clustering, we recapitulated the classification of known AT/RT subgroups. Synchronous brain and kidney tumors from the same patient showed different patterns of either copy number variants, single-nucleotide variants, and/or genome-wide DNA methylation, suggestive of non-clonal origin. Furthermore, we demonstrated that a lung and abdominal metastasis from two patients shared overlapping molecular features with the patient’s primary kidney tumor, indicating the likely origin of the metastasis. In addition to the SMARCB1 events, we
INTRODUCTION

Rhabdoid tumors (RT) are rare, malignant tumors diagnosed most often in early childhood. RTs are classified according to their anatomical location and most often arise in the brain (atypical teratoid/rhabdoid tumor; AT/RT) and/or extracranially, usually in the kidney (RTK) and sometimes in other soft tissues like muscles (1, 2). In the United States, AT/RT represents 10% of primary brain and central nervous system (CNS) tumors diagnosed in individuals less than 1 year of age (1). RTKs account for 18% of all renal tumors diagnosed in infants (2). Because of the rarity and aggressiveness of RTs and given the young age of many patients, there is no defined standard of care, and RTs remain one of the most lethal childhood tumors with overall survival rates <50% (3–5).

Almost all cases of RT, regardless of anatomical site, are molecularly characterized by the biallelic alteration of SMARCB1, leading to complete inactivation of the gene and, more rarely, inactivation of SMARCA4 in a germline or somatic setting (6–8). SMARCB1, also called INI1/BAF47/SNF5, is an established tumor suppressor at 22q11.2 that encodes a subunit protein of the SWI/SNF chromatin remodeling complex (9). In approximately 35% of individuals diagnosed with an AT/RT or RTK, one of the SMARCB1 alterations is present in the germline, predisposing the individual to the development of rhabdoid tumors (10, 11).

Despite the commonality of being driven by SMARCB1 or SMARCA4 loss, there is molecular and clinical heterogeneity among AT/RT. There are three known DNA methylation subgroups associated with AT/RT, referred to as TYR (characterized by the overexpression of melanosomal genes), SHH (characterized by the overexpression of sonic hedgehog signaling pathways), and MYC (characterized by the overexpression of both MYC proto-oncogene and HOX cluster genes) (12–14). AT/RT-TYR are diagnosed in the youngest population group (median age of diagnosis: 12 months) and usually arise in an infratentorial location (75%). AT/RT-SHH are predominantly supratentorial in location (65%) and are diagnosed in individuals with a median age of 20 months. AT/RT-MYC arise in the supratentorial region (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and represent the oldest population group (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and are diagnosed in individuals with a median age of 20 months. AT/RT-MYC arise in the supratentorial region (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and represent the oldest population group (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and are diagnosed in individuals with a median age of 20 months. AT/RT-MYC arise in the supratentorial region (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and represent the oldest population group (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and are diagnosed in individuals with a median age of 20 months. AT/RT-MYC arise in the supratentorial region (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and represent the oldest population group (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and are diagnosed in individuals with a median age of 20 months. AT/RT-MYC arise in the supratentorial region (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and represent the oldest population group (50%), the infratentorial region (38%), and even extracranially in the spinal cord (12%) and are diagnosed in individuals with a median age of 20 months.
Exome Sequencing and Analysis

Sequencing libraries were prepared for exome sequencing using NEBNext Ultra II FS DNA library prep kit (New England BioLabs). First, target enrichment by hybrid capture was performed by combining xGen Exome Research Panel with the xGenCNV Backbone and Cancer-Enriched Panels-Tech Access (Integrated DNA Technologies). The xGen exome panel (catalog number 10005153) targets 19,433 genes with a total probe coverage encompassing 39 Mb of genomic space, while the xGenCNV backbone panel (catalog number 1080569) consists of 9,115 individually synthesized probes combined with an additional 1,855 probes enriching cancer-associated gene regions. Libraries were then generated using the NEBNext Ultra II FS kit, and paired-end 151-bp reads were generated on NovaSeq6000. Alignment to human reference genome build GRCh38 and secondary analysis were performed using our previously published pipeline (17).

Germline variants were called using GATK’s HaplotypeCaller. The variants were then filtered based on the following characteristics: gnomAD population frequency <0.0001, depth of sequencing ≥8 reads, variant within protein-coding region or within 3 base pairs of canonical splice site, and presence of the gene within a previously published cancer predisposition list of 565 genes (18). VarScan2 and GATK were used to assess copy number variants (CNVs) and to detect loss of heterozygosity across all chromosomes (19). Copy number variation plots were generated from Varscan2-called segment files and plotted by centering around a zero-point determined by the median log-2 value of the segments of the first five chromosomes. Invariant copy data based on log-2 ratios were plotted as 100-bp windows in blue, wherein copy number variant segments were plotted as a red line by corresponding log-2 copy ratio and position. Loss of heterozygosity (LOH) data were plotted for tumor samples using the position (X axis) and variant allele frequency (VAF; Y axis) of called alleles filtered by a list of known biallelic sites. Points falling outside of an expected normal range of 25 to 75% were marked as LOH-supporting.

Somatic variants were called using MuTect2 (20). Somatic nonsynonymous SNVs and small insertions or deletions (indels) were filtered for quality (site quality ≥100), population frequency (gnomAD population frequency <0.0001), absence in the germline comparator sample, somatic alternate allele read depth (≥4 reads), minimum tumor VAF ≥5%, and gene location within a coding or splice site (≤3 base pairs) region. Variants passing all the aforementioned filters were manually reviewed in Integrated Genomics Viewer and then analyzed for the presence of the variant within a previously defined cancer hotspot (21) or the presence of the gene within a previously published cancer predisposition list of 565 genes (18). VarScan2 and GATK were used to assess CNVs and loss of heterozygosity across all chromosomes (19). Copy number variation and LOH data plots were generated as described for germline CNVs.

DNA Array-Based Methylation Profiling

For each tumor studied, 250–500 ng of input DNA was bisulfite-converted (catalog number D5006, Zymo Research, Irvine, CA, USA) and, if applicable, treated using the Illumina FFPE restoration process (catalog number WG-321-1002, Illumina, San Diego, CA, USA). Bisulfite-converted DNAs, including methylated human DNA controls (catalog number D5014, Zymo Research, Irvine, CA, USA), were hybridized to the Infinium Methylation EPIC BeadChip (catalog number WG-317-1001, Illumina, San Diego, CA, USA) following the Illumina Infinium HD Methylation protocol. Beadchips were imaged on the Illumina iScan System, and the resulting raw IDAT files were processed through a local installation of the German Cancer Research Center (DKFZ) DNA Methylation Brain Tumor Classifier, version 11b4 or 11b6 (22, 23). Uniform manifold approximation and projection (UMAP) plots were generated to assess the unsupervised clustering of the studied AT/RT samples, where only the most differentially methylated probes were considered. For comparison of our study samples with external DKFZ embryonal tumor samples (i.e., AT/RT, medulloblastomas, and embryonal tumors with multilayered rosettes), standard deviation ≥0.25 was used, which included 30,549 most differentially methylated probes for clustering analyses.

RNA Sequencing and Gene Expression Analysis

Tumor RNA was subjected to DNase treatment and ribodepletion prior to library construction using NEBNext Ultra II Directional RNA library prep kit for Illumina (New England BioLabs). Paired-end 151-bp reads were generated on Illumina HiSeq 4000 and aligned to the human genome reference sequence build GRCh38. Alignment was performed using a custom in-house pipeline and the splice-aware aligner STAR (24). Clustering was performed by principal component analysis (PCA) on log10(x + 1) and quantile-normalized DESeq2 expression values using a panel of 36 genes with known relevance to AT/RT subtyping for MYC (HOTAIR, HOXCA5/5′/6/8/9/10/11/12/13/AS1/AS5, and MYC), SHH (ASCL1, BOC, CDH6, DLL1/3, DTX1, GLI2, HES1/5/6, MYCN, and PTH1), and TYR (BMP4, DCT, DNAH11, FGFR2, JAK1, MITF, OTX2, PDGFRB, SPEF1, TYR, and VEGFA) groups (13).

Clonality Analysis

We used superFreq with default parameters to determine clonality (25). superFreq uses exome BAM files from tumor samples and identifies tumor-specific single-nucleotide variants, indels, and copy number variants to track clones across multiple samples from the same patient.

RESULTS

Tissue Pathology

The pathology review typically estimated a high tumor cellularity/content (average, 95%; range, 90–100%) and a wide range of necrosis (average, 12%; range, 0–40%) for all tumors studied (Table 1). As described in the clinical summaries (Supplementary File- Case Descriptions), the histologic findings in all tumors were determined by board-certified
pathologists and were consistent with either AT/RT or extracranial RT supported by loss of INI1 staining.

Genomic Analysis

The average exome sequencing coverage depth for the tumor samples was 241X (range: 181X–289X) and for the germline comparator samples was 216X (range: 186X–266X). For all samples, an average of 97.9% of coding bases was covered by at least 20 reads (range, 97.0–98.6%) (Supplementary Table S1).

Germline Analysis

All three patients had a pathogenic germline alteration affecting SMARCB1 identified by exome sequencing (Table 1). Patient 1 had a heterozygous frameshift variant in SMARCB1 (p.Pro215Leufs*14), while patients 2 and 3 had a large deletion (>1 Mb) of chr22q11, a region which includes the SMARCB1 gene, present in germline comparator tissue, thus confirming a diagnosis of rhabdoid tumor predisposition syndrome for all three.

Somatic Analysis

We observed a second somatic hit in SMARCB1 in all tumor specimens via LOH of chr22, inclusive of the SMARCB1 gene region. In patient 1, although heterozygous in the germline (48% VAF), the p.Pro215Leufs*14 variant exhibited much higher allele frequencies in all three tumor specimens (87% in primary brain, 68% in primary kidney, and 82% in lung metastasis) because of extensive copy-neutral LOH across chromosome 22q in all three tumor specimens (Supplementary Figures S1A–C). In patient 2, the chr22 deletion appeared homozygous in the patient’s primary brain and primary kidney tumors due to copy-neutral LOH across the entirety of chromosome 22 (Supplementary Figures S1D, E). We made similar observations in patient 3, who harbored a slightly smaller germline deletion on chr22 (1.34 Mb) that appeared homozygous in both primary kidney and metastatic abdominal tumors due to copy-neutral LOH affecting the entire chromosome (Supplementary Figures S1F, G).

DNA Methylation Profiling and Gene Expression Clustering and CNV Analysis Reveal Heterogeneity Between Tumors From the Same Patient

We generated DNA methylation profiles using Illumina EPIC 850K microarray for our cohort of tumors and analyzed the data using the DKFZ brain tumor methylation classifier v11b4 or v11b6, which provides the classification of 184 known central nervous system tumors (22). All tumors, including intra- and extracranial tumors, matched most closely with the methylation family of AT/RT, and all had confidence scores >0.90 (range: 0.9421–0.9997; Table 1). The brain tumor methylation classifier also assigns samples to different methylation subgroups or classes within the AT/RT family. In our cohort, one brain sample was predicted to be a TYR subgroup and one was predicted to be a SHH subgroup, while the other five samples (all non-CNS) were predicted to be MYC subgroups. Synchronous tumors from the same patient (patients 1 and 2) demonstrated epigenetic heterogeneity and were assigned different methylation subgroups, as visualized by the appearance in distinct UMAP clusters alongside other embryonal tumors from the DKFZ database (Supplementary Figure S2). The primary RTK and abdominal metastatic tumors from patient 3 were both classified as MYC and clustered together.

We also performed RNA-seq on all tumors, yielding >80,000,000 total reads for each RNA sample (Supplementary Table S1). To explore the heterogeneity of gene expression between the subgroups of RTs, we performed PCA of the RNA-seq data using 36 genes (see “Methods”) known to be divergently expressed in specific AT/RT subgroups, which include TYR/MITF/others for TYR subgroup, NOTCH signaling genes (e.g., ASCL1, HESS/6, and DLL1/3) and SHH signaling genes (e.g., MYCN and GLI2) for SHH subgroup, and MYC/HOTAIR/HOXC cluster genes for MYC subgroup (13). Similar to our methylation clustering, synchronous brain and extracranial tumors from the same patient demonstrated a variation in expression profiles and appeared in distinct clusters (Supplementary Figure S3). The resultant gene

| Table 1 | Summary of molecular findings. |
|---------|--------------------------------|
| **ID** | **Comparatortissue** | **GermlineSMARCB1** | **Tumorsite** | **Tumorcontent** | **Necrosis** | **CNS family (methylation score)** | **CNS AT/RT class (methylation score)** |
| Patient 1 | Blood | p.Pro215Leufs*14 | Brain | 96% | 1% | AT/RT (0.9997)* | TYR (0.9997)* |
| Patient 1 | Blood | | Kidney | 90% | 30% | AT/RT (0.9421)* | MYC (0.9078)* |
| Patient 1 | Blood | | Lung (metastatic) | 90% | 40% | AT/RT (0.9998)* | MYC (0.9977)* |
| Patient 1 | Blood | | Brain | 100% | 0% | AT/RT (0.9980)* | SHH (0.9986)* |
| Patient 2 | Kidney, non-tumor | 1.88 Mb deletion at 22q11.22-q11.23 | Kidney | 98% | 5% | AT/RT (0.9971)* | MYC (0.9967)* |
| Patient 2 | Kidney, non-tumor | | Kidney | 100% | 0% | AT/RT (0.9997)* | MYC (0.9997)* |
| Patient 3 | Abdomen (metastatic) | 1.34 Mb deletion at 22q11.22-q11.23 | Abdomen (metastatic) | 90% | 10% | AT/RT (0.9932)* | MYC (0.9823)* |

Unless otherwise indicated, all tissue specimens were from a primary tumor. The estimates of tumor content and necrosis are based on a pathology review. AT/RT, atypical teratoid rhabdoid tumor; MYC, MYC gene subgroup of AT/RT; SHH, sonic hedgehog subgroup of AT/RT; TYR, tyrosinase subgroup of AT/RT.

*Classifier versions used for the Heidelberg Brain Tumor and Sarcoma Classifiers: v11b4 CNS classifier.

**Classifier versions used for the Heidelberg Brain Tumor and Sarcoma Classifiers: v11b6 CNS classifier.
expression clustering data supported the subgroup classification predicted by methylation analysis for each sample.

**Clonal Tracking Using Single-Nucleotide Variants and Copy Number Variations Reveals Heterogeneity Between Tumors From the Same Patient**

**Patient 1**

While all samples possess second-hit somatic events resulting in the loss of any functional SMARCB1 allele, the brain lesion demonstrated a whole-chromosome loss of chr22, whereas the two extracranial samples exhibited LOH of chr22q only. Clonality analysis differentiated the brain and extracranial lesions into two distinct tumorigenic origins on the basis of a number of other variations. Of the 25 SNVs included in clonal clustering, none was found to be shared between the brain and extracranial tumors (Figure 1 and Supplementary Table S2). The kidney and lung tumors were found to be closely related, with the kidney and lung tumors sharing four SNVs. Like the patient’s kidney tumor, the lung metastasis was also classified as MYC subgroup based on methylation profiling, further supporting the probable shared clonal origin of these two extracranial tumors. Each extracranial sample was found to possess a uniquely derived subclone, with kidney and lung samples gaining a number of exclusive SNVs (7 and 12, respectively). The subclone identified in the brain sample was differentiated only by one SNV, an intronic variant in GPKOW (Supplementary Table S2). No other CNVs besides chr22 or chr22q LOH were identified in any of the tumors (Supplementary Figures S1A–C). Despite the presence of two independent tumor lineages and as many as five distinct clones, no new diagnostic, prognostic, or therapeutically applicable SNVs or CNVs were found in any clones beyond the SMARCB1 events.

**Patient 2**

Clonality analysis indicated a shared origin for kidney and brain samples as the most parsimonious clonal history for this case. However, only a single event—whole-chromosome copy-neutral LOH of chr22—is shared between the two tumors. While the kidney lesion was not found to have any SNVs or CNVs beyond the initial chr22 LOH, the copy number analysis of the brain tumor revealed several chromosomal aberrations and two distinct sequentially derived clones (Figure 2). The first clone...
added three SNVs and nine full-chromosome CNV events—a single-copy gain of chr2, chr7, chr11, chr15, chr19, and chr20; balanced two-copy gains of chr8 and chr18; and a copy-neutral LOH of chr5 (Figure 2 and Supplementary Figures 1D, E). The second, further-derived clone (green) added an additional of two SNVs plus a loss of heterozygosity of chr14. These observed molecular differences between the brain and kidney tumors is further supported by their classification into different methylation subgroups (SHH and MYC, respectively), indicating that the tumors do not share a clonal origin. Aside from chr22 LOH, none of the SNVs or CNVs unique to the brain lesion was found to be meaningful in terms of prognosis, diagnosis, or therapeutic potential for AT/RT (26).

DISCUSSION

We analyzed seven tumor tissue samples from three pediatric patients diagnosed with rhabdoid tumors of the brain and/or extracranial sites and aimed to systematically assess each individual case using a multimodal approach of DNA and RNA sequencing plus methylation profiling. As expected, all tumors exhibited biallelic inactivation of SMARCB1, including a germline SMARCB1 alteration in every patient. We also analyzed tumors using DNA array-based methylation and RNA-seq-based gene expression analyses to characterize tumors based on known molecular subgroups of AT/RT (12). Our use of the v11b4/b6 brain tumor methylation classifier provided confident classifications for tumors as either MYC, SHH, or TYR AT/RT subgroups, even for extracranial RTs (22). We confirmed the use of analyzing gene expression data from RNA-seq as an orthogonal method for identifying distinct molecular AT/RT subgroups by evaluating the expression of known subgroup-specific marker genes (13).

Our integrated analysis of synchronous tumors from the same patient revealed several interesting findings. First, RTs originating in and outside the brain in each case showed molecularly heterogeneous methylation profiling and were classified as different subgroups (patient 1 brain = TYR and kidney = MYC; patient 2 brain = SHH and kidney = MYC). While the finding of divergent methylation patterns in synchronous rhabdoid tumors has been reported before, our integrated analyses using exome
sequencing and clonal tracking demonstrated that, aside from chr22 LOH, the brain and extracranial tumors demonstrated further molecular heterogeneity and never shared any tumor SNVs or CNVs (Figures 1, 2) (15, 27). Although the tumors from patient 2 were initially predicted to share a clonal origin (using superFreq software), this is likely because of the commonality of chr22 LOH and the fact that the kidney tumor did not possess any other CNVs or SNVs. In fact, LOH of chr22 or chr22q was a ubiquitous event observed in all tumors within our cohort and is likely the most common mechanism for a second hit in SMARCB1 in patients with rhabdoid tumor predisposition syndrome (i.e., germline SMARCB1 mutation). As chr22 LOH is common in this tumor type, it is most likely that the true explanation is that an indistinguishable event occurred in two separate instances for the brain and extracranial RT to have been formed—for example, in patient 2. This explanation is supported by the high cellularity of the first derived brain clone (red) in patient 2, suggesting that it may be the true tumorigenic ancestor of the brain lesion (Figure 2). Due to the lack of any other shared genomic alterations (besides chr22 LOH) and the lack of a biological mechanism for metastasis between the kidney and brain, the more plausible explanation is that the loss of chr22 has occurred twice separately. However, as the events alone are indistinguishable, a metastatic event is conceivably possible and cannot be excluded with certainty. In patient 3, we observed the same methylation profile for both kidney and abdominal lesions, and additionally we identified two shared SNVs between the two tumors at >40% VAF, indicating a likely shared clonal origin (Supplementary Table S2). While most of the tumors in our cohort appeared to derive clones, it was composed of either non-coding SNVs (intronic or promoter regions) or other passenger mutations, primarily nonsynonymous variants in genes not previously associated with cancer. Interestingly, only one tumor in our cohort (patient 2 brain) had additional CNVs besides chr22 LOH, highlighting the importance of using exome sequencing to study the tumors fully.

Given that AT/RT is a heterogenous disease with different subgroups, the goal is that molecular studies and findings can be used to guide therapy and improve patient outcomes. Several epidemiological studies have independently reported that patients with AT/RT-TYR or ASCL1-expressing (NOTCH signaling) ATRT-SHH tumors have a better prognosis, but more analyses on larger prospective cohorts are needed to confirm these findings (12, 28–30). In addition, several preclinical studies have identified drugs and drug-like inhibitors with different therapeutic effects in molecular subgroups of AT/RTs (31–33). Therefore, it is likely that molecular subgrouping of rhabdoid tumors is expected to affect patient management in the future, as there may be differences in response to different therapies and overall survival. While our findings are of biological interest, there may also be clinical value in using comprehensive molecular profiling to diagnose and classify rhabdoid synchronous tumors, particularly given the potential prognostic and therapeutic implications for different rhabdoid tumor subgroups.

DATA AVAILABILITY STATEMENT

DNA and RNA sequencing data for this study has been deposited to dbGaP under accession number phs001820.v1.p1. dbGaP identifiers for each sample are listed in Supplementary Table 1.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board at Nationwide Children’s Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor (s’) legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

KM: Conceptualization, Writing- Original Draft; GW: Formal analysis, Writing- Original Draft; SL: Formal analysis; KS: Formal analysis, Writing - Review and Editing; SC: Formal analysis, Writing- Original Draft; LV: Formal analysis; AB: Formal analysis; OG: Formal analysis; BK: Formal analysis; PW: Supervision; CP: Resources; DB: Resources, Writing - Review and Editing; SK: Resources; DK: Resources; MR: Resources; AS: Resources; RS: Resources; MS: Resources; JL: Resources; RW: Supervision; CC: Supervision, Writing - Review and Editing; EM: Conceptualization, Writing- Original Draft; DCK: Conceptualization, Writing- Original Draft. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Nationwide Foundation Pediatric Innovation Fund.

ACKNOWLEDGMENTS

We are grateful for the patients and families who participated in this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.932337/full#supplementary-material

Supplementary Figure 1 | Genome-wide copy number plots. In the top window of each panel are copy number plots, where blue points represent the log2 ratio for
the tumor relative to the normal specimen and red lines represent copy number variants segments as called by GATK. The heterozygosity plots (bottom window of each panel) show the tumor variant allele frequency (VAF) for heterozygous germline variants, which are colored red if they exhibit significant evidence of loss of heterozygosity (LOH) from the expected 50% VAF. The horizontal blue lines indicate contiguous LOH segments. Included are patient 1 primary brain tumor heterozygosity (LOH) from the expected 50% VAF. The horizontal blue lines indicate variants, which are colored red if they exhibit significant evidence of loss of heterozygosity (LOH) from the expected 50% VAF. The horizontal blue lines indicate.

Supplementary Figure 2 | Unsupervised clustering by uniform manifold approximation and projection (UMAP) of embryonal tumors indicates the grouping of rhabdoid tumor (RT) tumors by methylation classification. The seven samples from our cohort were compared to 345 embryonal tumors [atypical teratoid (AT)/RT, medulloblastoma, and embryonal tumors with multilayered rosettes] described by Capper et al. [22] by unsupervised UMAP clustering, using the most differentially methylated probes (standard deviation ≥0.25, n = 30549 probes). The seven tumors from our cohort were grouped according to their predicted classifications, as assigned by the DKFZ CNS Classifier v11b4/v11b6. The samples from our cohort are outlined in black and are filled with color by their AT/RT subgroup as called by previous methylation profiling.

Supplementary Figure 3 | Clustering by RNA-seq expression recapitulates subgrouping of rhabdoid tumors. Principal component analysis was performed by using 36 genes (see “Methods”) known to be differentially expressed in distinct AT/RT subgroups. The samples are colored by their RT subgroup as called by methylation profiling and as central nervous system (CNS) or non-CNS indicative of the tumor location.

Supplementary Table 1 | Exome sequencing metrics. Top: the 10 samples obtained from individuals are listed along with the type of tissue (tumor or comparator), sample type, mean depth of target exon coverage, and percent of targeted bases per gene sequenced to 20× coverage. Bottom: metrics from RNA-sequencing. The seven samples upon which RNA-seq was performed are listed along with tumor type, sample preservation type, total number of reads, number of reads mapped to GRCh38, and number of coding and untranscribed region reads. The corresponding dbGap ID for each sample is listed. FFPE, formalin-fixed paraffin-embedded; GRCh38, human genome assembly (hg38) from Genome Reference Consortium; UTR, untranslated region.

Supplementary Table 2 | Single-nucleotide variants and copy number variants detected in clonal analysis. Variants detected in clonal tracking are listed with corresponding variant allele frequencies predicted from exome sequencing data. The color of the clone corresponding to –5 is also noted.

CASE DESCRIPTIONS | Clinical history of all three patients, which includes diagnostic details, treatment regimens, and the current clinical status of each patient.

REFERENCES

1. Ostrom QT, Chen Y P, Dordick A, Farah P, Gittleman H, et al. The Descriptive Epidemiology of Atypical Teratoid/Rhabdoid Tumors in the United States, 2001-2010. Neuro Oncol (2014) 16(10):1392–9. doi: 10.1093/neuonc/not090
2. Brennan B, Stiller C, Bourdeaut F. Extracranial Rhabdoid Tumours: What We Have Learned So Far and Future Directions. Lancet Oncol (2013) 14(8):e29–36. doi: 10.1016/S1470-2045(13)70088-3
3. Shan Y, Cai J, Han Y, Xie C, Gao H, Zhang L, et al. An Analysis of the Diagnosis, Clinical Characteristics, Treatment, and Survival Outcomes of 36 Extranarial Malignant Rhabdoid Tumor Patients. Transl Pediatr (2021) 10 (6):1598–609. doi: 10.21037/tp-20-459
4. Cai W, Liu X, Ge W, Wu D, Xu J, Bai R, et al. Factors Affecting the Outcomes of Patients With Malignant Rhabdoid Tumors: A Population-Based Study. Int J Med Sci (2021) 18(4):911–20. doi: 10.7890/jims.51186
5. Pai Panandiker AS, Merchant TE, Beltran C, Wu S, Sharma S, Boop FA, et al. Sequencing of Local Therapy Affects the Pattern of Treatment Failure and Survival in Children With Atypical Teratoid Rhabdoid Tumors of the Central Nervous System. Int J Radiat Oncol Biol Phys (2012) 82(5):1756–63. doi: 10.1016/j.ijrobp.2011.02.059
6. Verstege I, Sevenet N, Lange J, Rousseaux-Merc F, Ambros P, Handegretner R, et al. Truncating Mutations of Hsnf5/INI1 in Pediatric Aggressive Brain Tumors. Nature (1998) 394(6768):203–6. doi: 10.1038/28212
7. Hasselblatt M, Nagel I, Oyen F, Bartelheim K, Russell RB, Schuller U, et al. SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumors Are Associated With Inherited Germline Alterations and Poor Prognosis. Acta Neuropathol (2014) 128(3):453–6. doi: 10.1007/s00401-014-1323-x
8. Schnepenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al. Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family With Rhabdoid Tumor Predisposition Syndrome. Am J Hum Genet (2010) 86(2):279–84. doi: 10.1016/j.ajhg.2010.01.013
9. Kohashi K, Oda Y. Oncogenic Roles of SMARCB1/INI1 and its Deficient Tumors. Cancer Sci (2017) 108(4):547–52. doi: 10.1111/cas.13173
10. Eaton KW, Tooki LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 Mutations in Familial and Sporadic Rhabdoid Tumors. Pediatr Blood Cancer (2011) 56(1):7–15. doi: 10.1002/hlc.22831
11. Biegel JA, Zhou JY, Rorke LB, Sternberg C, Wainwright LM, Fogelgren B, Germ-Line and Acquired Mutations of INI1 in Atypical Teratoid and Rhabdoid Tumors. Cancer Res (1999) 59(1):74–9.
12. Ho B, Johann PD, Grabovska Y, De Dieu Andrianterranja MG, Yao F, Fruhwald M, et al. Molecular Subgrouping of Atypical Teratoid/Rhabdoid Tumors-a Reinvestigation and Current Consensus. Neuro Oncol (2020) 22 (3):613–24. doi: 10.1093/neojc/noa235
13. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, et al. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups With Distinct Enhancer Landscapes. Cancer Cell (2016) 29 (3):379–93. doi: 10.1016/j.cccel.2016.02.001
14. Torchia J, Golbiouri BY, Peng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. Integrated (Epi-)Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell (2016) 30(6):891–908. doi: 10.1016/j.cccel.2016.11.003
15. Pinto EM, Hamideh D, Bahrami A, Orr BA, Lin T, Pounds S, et al. Malignant Rhabdoid Tumors Originating Within and Outside the Central Nervous System are Clinically and Molecularly Heterogeneous. Acta Neuropathol (2018) 136(2):315–26. doi: 10.1007/s00401-018-1814-2
16. Chun HE, Johann PD, Milne K, Zapatka M, Buellesbach A, Ishaque N, et al. Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors With Cytotoxic T Cell Infiltration. Cell Rep (2019) 29(8):2338–41 e7. doi: 10.1016/j.celrep.2019.10.013
17. Kelly BJ, Fitch JR, Hu Y, Corsmeier DJ, Zhong H, Wetzel AN, et al. Churchill: An Ultra-Fast, Deterministic, Highly Scalable and Balanced Parallelization Strategy for the Discovery of Human Genetic Variation in Clinical and Population-Scale Genomics. Genome Biol (2015) 16:6. doi: 10.1186/s13059-014-0577-x
18. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med (2015) 373(24):2336–46. doi: 10.1056/NEJMoa1508054
19. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: Somatic Mutation and Copy Number Alteration Discovery in Cancer by Exome Sequencing. Genome Res (2012) 22(3):568–76. doi: 10.1101/ gr.129684.111
20. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples. Nat Biotechnol (2013) 31(3):213–9. doi: 10.1038/nbt.2514
21. Chang MT, Bhattacharai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery (2018) 8(2):174–83. doi: 10.1158/2155-8290-CD-17-0321
22. Capper D, Jones DTW, Sill M, Hovestadt V, Schirmpf D, Sturm D, et al. DNA Methylation-Based Classification of Central Nervous System Tumours. Nature (2018) 553(7697):469–74. doi: 10.1038/nature26000
23. Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma Classification by DNA Methylation Profiling. *Nat Commun* (2021) 12(1):498. doi: 10.1038/s41467-020-20603-4

24. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast Universal RNA-Seq Aligner. *Bioinformatics* (2013) 29(1):15–21. doi: 10.1093/bioinformatics/bts635

25. Flensburg C, Sargeant T, Oshlack A, Majewski IJ. SuperFreq: Integrated Mutation Detection and Clonal Tracking in Cancer. *PloS Comput Biol* (2020) 16(2):e1007603. doi: 10.1371/journal.pcbi.1007603

26. Mikhail FM, Biegel JA, Cooley LD, Dubuc AM, Hirsch B, Horner VL, et al. Technical Laboratory Standards for Interpretation and Reporting of Acquired Copy-Number Abnormalities and Copy-Neutral Loss of Heterozygosity in Neoplastic Disorders: A Joint Consensus Recommendation From the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). *Genet Med* (2019) 21(9):1903–16. doi: 10.1038/s41436-019-0545-7

27. Thomas C, Knerlich-Lukoschus F, Reinhard H, Johann PD, Sturm D, Sahm F, et al. Two Molecurally Distinct Atypical Teratoid/Rhabdoid Tumors (or Tumor Components) Occurring in an Infant With Rhabdoid Tumor Predisposition Syndrome 1. *Acta Neuropathol* (2019) 137(5):847–50. doi: 10.1007/s00401-019-02001-3

28. Fruhwald MC, Hasselblatt M, Nemes K, Bens S, Steinbugl M, Johann PD, et al. Age and DNA Methylation Subgroup as Potential Independent Risk Factors for Treatment Stratification in Children With Atypical Teratoid/Rhabdoid Tumors. *Neuro Oncol* (2020) 22(7):1006–17. doi: 10.1093/neuonc/noz244

29. Reddy AT, Strother DR, Judkins AR, Burger PC, Pollack IF, Kralo MD, et al. Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial Acns0333. *J Clin Oncol* (2020) 38 (11):1175–85. doi: 10.1200/JCO.19.01776

30. Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, et al. Relevance of Molecular Groups in Children With Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results From Prospective St. Jude Multi-Institutional Trials. *Clin Cancer Res* (2021) 27(10):2679–89. doi: 10.1158/1078-0432.CCR-20-4731

31. Meel MH, Guillen Navarro M, de Gooijer MC, Metselaar DS, Waranecki P, Breur M, et al. MEK/MELK Inhibition and Blood-Brain Barrier Deficiencies in Atypical Teratoid/Rhabdoid Tumors. *Neuro Oncol* (2020) 22(1):58–69. doi: 10.1093/neuonc/noz151

32. Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, et al. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition With 6-Diazo-5-Oxo-L-Norleucine. *Clin Cancer Res* (2019) 25(19):5925–36. doi: 10.1158/1078-0432.CCR-19-0189

33. Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, et al. Inhibition of MYC Attenuates Tumor Cell Self-Renewal and Promotes Senescence in SMARCBl-Deficient Group 2 Atypical Teratoid Rhabdoid Tumors to Suppress Tumor Growth In Vivo. *Int J Cancer* (2019) 144(8):1983–95. doi: 10.1002/ijc.31873

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Miller, Wheeler, LaHaye, Schieffer, Cearlock, Venkata, Bravo, Grischow, Kelly, White, Pierson, Boué, Koo, Klawinski, Ranalli, Shaikhouni, Salloum, Shutara, Leonard, Wilson, Cottrell, Mardis and Koboldt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.